000 -LEADER |
fixed length control field |
04221nam a22006377a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
200131s20192019 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
1522-1946 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1002/ccd.28661 [doi] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
Classification number |
31883294 |
100 ## - MAIN ENTRY--PERSONAL NAME |
Personal name |
Garcia-Garcia, Hector M |
100 ## - MAIN ENTRY--PERSONAL NAME |
Personal name |
Yacob, Omar |
190 ## - |
-- |
Adamo M |
190 ## - |
-- |
Ando G |
190 ## - |
-- |
Boccuzzi G |
190 ## - |
-- |
Briguori C |
190 ## - |
-- |
Calabro P |
190 ## - |
-- |
Contarini M |
190 ## - |
-- |
Diletti R |
190 ## - |
-- |
Frigoli E |
190 ## - |
-- |
Garcia-Garcia HM |
190 ## - |
-- |
Garducci S |
190 ## - |
-- |
Karagiannis A |
190 ## - |
-- |
Limbruno U |
190 ## - |
-- |
Palmieri C |
190 ## - |
-- |
Picchi A |
190 ## - |
-- |
Rigattieri S |
190 ## - |
-- |
Russo F |
190 ## - |
-- |
Sardella G |
190 ## - |
-- |
Soud M |
190 ## - |
-- |
Valgimigli M |
190 ## - |
-- |
Varbella F |
190 ## - |
-- |
Yacob O |
190 ## - |
-- |
Zimarino M |
245 ## - TITLE STATEMENT |
Title |
Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. |
251 ## - |
-- |
Catheterization & Cardiovascular Interventions. 2019 Dec 28 |
252 ## - |
-- |
Catheter Cardiovasc Interv. 2019 Dec 28 |
253 ## - |
-- |
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Date of publication, distribution, etc. |
2019 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
-- |
aheadofprint |
269 ## - |
-- |
FY2020 |
501 ## - WITH NOTE |
With note |
Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006 |
520 ## - SUMMARY, ETC. |
Summary, etc. |
BACKGROUND: Residual stent strut thrombosis after primary percutaneous coronary intervention (PCI), negatively affects myocardial perfusion, may increase stent thrombosis risk, and it is associated with neointima hyperplasia at follow-up. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
CONCLUSIONS: The administration of bivalirudin after primary PCI significantly reduces residual stent strut thrombosis when compared to UFH. This observation should be considered hypothesis-generating since the heparin-treated patients were not randomly allocated. Copyright (c) 2019 Wiley Periodicals, Inc. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
METHODS: Multi-vessel STEMI patients undergoing primary PCI and requiring staged intervention were selected among those randomly allocated to two different bivalirudin infusion regimens in the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) Treatment-Duration study. Those receiving heparin only were enrolled into a registry arm. Optical coherence tomography (OCT) of the infarct-related artery was performed at the end of primary PCI and 3-5 days thereafter during a staged intervention. The primary endpoint was the change in minimum flow area (DELTAMinFA) defined as (stent area + incomplete stent apposition [ISA] area) - (intraluminal defect + tissue prolapsed area) between the index and staged PCI. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
OBJECTIVES: To study the effectiveness of any bivalirudin infusion versus unfractionated heparin (UFH) infusion in reducing residual stent strut thrombosis in patients with ST-elevation myocardial infarction (STEMI). |
520 ## - SUMMARY, ETC. |
Summary, etc. |
RESULTS: 123 patients in bivalirudin arm and 28 patients in the UFH arm were included. Mean stent area, percentage of malapposed struts, and mean percent thrombotic area were comparable after index or staged PCI. The DELTAMinFA in the bivalirudin group was 0.25 versus 0.05 mm2 in the UFH group, which resulted in a between-group significant difference of 0.36 [95% CI: (0.05, 0.71); p = .02]. This was mostly related to a decrease in tissue protrusion in the bivalirudin group (p = .03). There was a trend towards more patients in the bivalirudin group who achieved a 5% difference in the percentage of OCT frames with the area >5% (p = .057). |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Geographic name |
MedStar Heart & Vascular Institute |
657 ## - INDEX TERM--FUNCTION |
Function |
Journal Article |
856 ## - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
https://dx.doi.org/10.1002/ccd.28661 |
857 ## - |
-- |
https://dx.doi.org/10.1002/ccd.28661 |
858 ## - |
-- |
Garcia-Garcia, Hector M |
-- |
https://orcid.org/0000-0001-5100-0471 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |